Complete remission of metastatic melanoma upon BRAF inhibitor treatment-what happens after discontinuation?

Melanoma Research

Volumn 25, Issue 4, 2015, Pages 362-366

  Tolk, Henrike ^a   Satzger, Imke ^a   Mohr, Peter ^b   Zimmer, Lisa ^c   Weide, Benjamin ^d   Schäd, Susanne ^e   Gutzmer, Ralf ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Elbe Klinikum Buxtehude   (Germany)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

^d UNIVERSITY OF TÜBINGEN   (Germany)

^e UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

BRAF inhibitor; BRAF mutation; melanoma

Indexed keywords

CANCER VACCINE; DABRAFENIB; DACARBAZINE; IPILIMUMAB; LACTATE DEHYDROGENASE; TRAMETINIB; VEMURAFENIB; ANTINEOPLASTIC AGENT; B RAF KINASE; BRAF PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; OXIME; SULFONAMIDE;

ADD ON THERAPY; ADULT; AGED; ARTHRALGIA; ARTICLE; AUTOIMMUNE COLITIS; AUTOIMMUNE DISEASE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CENTRAL SCOTOMA; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DISEASE COURSE; DRUG ERUPTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FAINTNESS; FEMALE; GENERAL CONDITION DETERIORATION; GLOMERULUS FILTRATION RATE; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTOCLASTIC VASCULITIS; LIVER FUNCTION TEST; LIVER METASTASIS; MACULOPAPULAR RASH; MALE; METASTATIC MELANOMA; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; PERICARDITIS; PRIORITY JOURNAL; QT PROLONGATION; RADIOFREQUENCY ABLATION; RETROSPECTIVE STUDY; RHABDOMYOLYSIS; SEX RATIO; TREATMENT DURATION; TREATMENT RESPONSE; YOUNG ADULT; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; GENETICS; MELANOMA; MULTICENTER STUDY; PATHOLOGY; SKIN NEOPLASMS; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; IMIDAZOLES; INDOLES; MALE; MELANOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OXIMES; PROTO-ONCOGENE PROTEINS B-RAF; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; SULFONAMIDES; YOUNG ADULT;

EID: 84936941910     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0000000000000169     Document Type: Article

References (15)

1. Lee JH, Choi JW, Kim YS. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. Br J Dermatol 2011; 164:776-784.
2. Jakob JA, Bassett RL Jr, Ng CS, Curry JL, Joseph RW, Alvarado GC, et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 2012; 118:4014-4023.
3. Greaves WO, Verma S, Patel KP, Davies MA, Barkoh BA, Galbincea JM, et al. Frequency and spectrum of BRAF mutations in a retrospective, singleinstitution study of 1112 cases of melanoma. J Mol Diagn 2013; 15:220-226.
4. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507-2516.
5. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, openlabel, phase 3 randomised controlled trial. Lancet 2012; 380:358-365.
6. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27:6199-6206.
7. Chapman PB, Hauschild A, Robert C, Larkin JMG, Haanen JBAG, Ribas A, et al. Updated overall survival (OS) results for BRIM-3, a phase III randomized open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma [abstract]. J Clin Oncol 2012; 30 (Suppl):8502.
8. McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, et al. Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutationpositive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 2014; 15:323-332.
9. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Milward M, et al. ABSTRACT 1092: an update on overall survival (OS) and follow-on therapies in BREAK-3, a phase III, randomized trial: dabrafenib (D) vs dacarbazine (DTIC) in patient (pts) with BRAF V600E mutation-positive metastatic melanoma (MM). Madrid, Spain: European Society for Medical Oncology (ESMO) Congress; 2014.
10. Das Thakur M, Salangsang F, Landman AS, Sellers WR, Pryer NK, Levesque MP, et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 2013; 494:251-255.
11. Koop A, Satzger I, Alter M, Kapp A, Hauschild A, Gutzmer R. Intermittent BRAF-inhibitor therapy is a feasible option: report of a patient with metastatic melanoma. Br J Dermatol 2014; 170:220-222.
12. Chan MM, Haydu LE, Menzies AM, Azer MW, Klein O, Lyle M, et al. The nature and management of metastatic melanoma after progression on BRAF inhibitors: effects of extended BRAF inhibition. Cancer 2014; 120:3142-3153.
13. Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov 2014; 4:80-93.
14. Sun C, Wang L, Huang S, Heynen GJ, Prahallad A, Robert C, et al. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature 2014; 508:118-122.
15. Seghers AC, Wilgenhof S, Lebbé C, Neyns B. Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor. Melanoma Res 2012; 22:466-472.